Nomic and Parse build a multimodal, time-resolved dataset for AI models of immune response. October 29, 2026 | Licensable foundational dataset combines 100 million single-cell RNA profiles with more than 11,000 quantitative protein profiles from healthy-donor perturbations, with leading biopharma partners already participating MONTREAL-(BUSINESS WIRE)-Nomic Bio Inc., a proteomics company, and Parse Biosciences, a provider of single-cell sequencing and a QIAGEN company, today announced their partnership to generate Cascade, a large-scale multimodal, time-resolved dataset designed to establish a foundational reference for healthy human immune response. Built from controlled perturbations across healthy donors, Cascade pairs single-cell transcriptomic measurements with quantitative secretome proteomics to capture how immune cell states change and how secreted protein signals evolve over time. The dataset will support the development and evaluation of AI models of immune biology and provide a framework that can be extended to disease-specific questions. A multimodal map of human immune response As models of biology become more ambitious, they increasingly require experimental datasets that capture multiple molecular layers, span larger numbers of cells and perturbations, and follow biological responses over time. Cascade was designed around those requirements. Using PBMCs from 12 healthy donors, it will pair single-cell transcriptomic and quantitative secretome measurements across multiple timepoints, creating a time-resolved view of how at least 14 immune cell types respond to individual and combinatorial cytokine, chemokine, and drug perturbations. In total, the dataset will include 100 million single-cell RNA-seq profiles, more than 11,000 proteomic profiles, and over 150,000 perturbation measurements. The time-resolved design captures biology that a single endpoint can miss, including early signals, transient responses, and delayed protein secretion. This allows researchers to follow how immune responses develop rather than observing only their final state, creating a stronger reference for modeling immune signaling and the effects of immune-modulating therapies. The resulting dataset provides a common multimodal reference that researchers can build upon with additional perturbations, disease contexts, donors, and data modalities. Because the experimental framework is extensible, Cascade can serve as a starting point for adding new biological contexts while maintaining continuity for model development and evaluation. Proteomics as a core data layer for AI biology "Many therapies aim to modulate cytokine signaling," said Milad Dagher, Chief Executive Officer of Nomic Bio. "To model those responses with AI, we need a strong reference for how healthy human immune cells respond across perturbations and time, including the proteins they release. Cascade creates that foundation and a framework to build on for disease-specific questions." Parse's GigaLab will perform single-cell RNA sequencing to capture how distinct immune cell types respond to each perturbation, while Nomic's Omni 1000 platform will profile more than 1,000 secreted proteins from the same samples. Nomic's quantitative protein measurements are designed to remain comparable across studies, making Cascade interoperable with future datasets spanning new donors, perturbations, and disease contexts. Linking the RNA and protein measurements by donor, perturbation, and time also creates opportunities for AI model development and evaluation. Researchers can, for example, test whether specific cellular responses predict downstream secreted-protein profiles, or hold out donors and perturbations to evaluate how well models generalize to unseen biology. These data can support model training, adaptation, benchmarking, and evaluation. "Cascade was designed from the beginning as a multimodal dataset," said Charlie Roco, Ph.D., Co-founder and Chief Technology Officer of Parse Biosciences. "The scale and structure of the study give researchers a common experimental framework for modeling immune response today and extending those models as new biological contexts and datasets are added." Industry leaders join as foundational partners Cascade has already attracted foundational partners across biopharma and computational drug discovery, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, reflecting demand for multimodal datasets that can support AI modeling, drug discovery, and deeper understanding of human immune response. Data generation for Cascade is underway. The dataset will be available for licensing, organizations interested in Cascade or working with Nomic on proteomic and multimodal datasets for AI and computational biology can learn more at info.nomic.bio/cascade. About Nomic Bio Nomic was founded to make measuring biology easier and enable scientists to extend lives by making proteomics accessible, scalable, and routine. Powered by its proprietary nELISA(R) technology, Nomic delivers large-scale, quantitative, and cost-effective protein data to accelerate discovery, development, and translation. Its end-to-end service combines flexible content, expert support, and analysis-ready outputs, enabling seamless integration of proteomics across all stages of drug and biomarker development. Nomic's mission is to make proteomics ubiquitous for modern biology. To learn more, visit nomic.bio or connect with us on LinkedIn. About Parse Biosciences Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Media Contacts Nomic Bio Michael B. Gonzales, PhD Vice President, Global Marketing Email: [email protected] Phone: 415.308.6467 Parse Biosciences Kaitie Kramer Vice President, Marketing Email: [email protected] Phone: 858.504.0455

Parse Biosciences, Nomic Bio to generate rna-seq, proteomic data for 100M cells. October 29, 2026 03:16 PM EDT NEW YORK - Qiagen subsidiary Parse Biosciences and Nomic Bio announced on Thursday that they will collaborate to generate a multimodal dataset of 100 million cells to provide insights into immune biology. Get the full story with GenomeWeb Premium. Premium Access Trial - only $95 for the first 90 days

Parse Biosciences launches Evercode MAX, enabling researchers to profile more cells and samples with greater flexibility. New modular platform gives researchers greater control over sample and cell throughput while optimizing value SEATTLE - Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode(TM) MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using...